These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 23751341)

  • 1. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery.
    Brough C; Williams RO
    Int J Pharm; 2013 Aug; 453(1):157-66. PubMed ID: 23751341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update.
    Jermain SV; Brough C; Williams RO
    Int J Pharm; 2018 Jan; 535(1-2):379-392. PubMed ID: 29128423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.
    Bikiaris DN
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1501-19. PubMed ID: 21919807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs.
    Vo CL; Park C; Lee BJ
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):799-813. PubMed ID: 24056053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.
    Vasconcelos T; Sarmento B; Costa P
    Drug Discov Today; 2007 Dec; 12(23-24):1068-75. PubMed ID: 18061887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs.
    Wang XQ; Zhang Q
    Eur J Pharm Biopharm; 2012 Oct; 82(2):219-29. PubMed ID: 22885229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective.
    van Hoogevest P; Liu X; Fahr A
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1481-500. PubMed ID: 21895540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the Preparation Process on the Properties of Amorphous Solid Dispersions.
    Huang S; Williams RO
    AAPS PharmSciTech; 2018 Jul; 19(5):1971-1984. PubMed ID: 28924730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid nanoparticles for the delivery of poorly water-soluble drugs.
    Bunjes H
    J Pharm Pharmacol; 2010 Nov; 62(11):1637-45. PubMed ID: 21039547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral formulation strategies to improve solubility of poorly water-soluble drugs.
    Singh A; Worku ZA; Van den Mooter G
    Expert Opin Drug Deliv; 2011 Oct; 8(10):1361-78. PubMed ID: 21810062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of injectable drug nanocrystals.
    Fuhrmann K; Gauthier MA; Leroux JC
    Mol Pharm; 2014 Jun; 11(6):1762-71. PubMed ID: 24766270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCS class IV drugs: Highly notorious candidates for formulation development.
    Ghadi R; Dand N
    J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid dispersions, part II: new strategies in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.
    Bikiaris DN
    Expert Opin Drug Deliv; 2011 Dec; 8(12):1663-80. PubMed ID: 21919806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations.
    Al-Hamidi H; Edwards AA; Mohammad MA; Nokhodchi A
    Colloids Surf B Biointerfaces; 2010 Mar; 76(1):170-8. PubMed ID: 19945828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging trends in the stabilization of amorphous drugs.
    Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
    Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
    Kawakami K
    Adv Drug Deliv Rev; 2012 May; 64(6):480-95. PubMed ID: 22265844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melt extrusion with poorly soluble drugs.
    Shah S; Maddineni S; Lu J; Repka MA
    Int J Pharm; 2013 Aug; 453(1):233-52. PubMed ID: 23178213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug nanoparticles: formulating poorly water-soluble compounds.
    Merisko-Liversidge EM; Liversidge GG
    Toxicol Pathol; 2008 Jan; 36(1):43-8. PubMed ID: 18337220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs.
    Davis M; Walker G
    J Control Release; 2018 Jan; 269():110-127. PubMed ID: 29117503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refining stability and dissolution rate of amorphous drug formulations.
    Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
    Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.